pharmaceuticals
pharmaceuticals Articles
KalVista Pharmaceuticals saw its shares absolutely explode early on Tuesday after it was announced that the firm would be collaborating with Merck.
Published:
Last Updated:
24/7 Wall St. has collected a few more catalysts that are coming up in October for biotech and pharmaceutical companies.
Published:
Last Updated:
ImmunoGen saw its shares make a sharp turn downward on Thursday morning after the stock has seen an incredible year of trading so far.
Published:
Last Updated:
Finally some good news out of Mylan, which potentially is bringing the shares back to about even for 2017.
Published:
Last Updated:
U.S. pharmaceutical and biotech stocks may have considerable upside if Credit Suisse's views come to pass. But this part of the market has not come without controversy in the past year and a half.
Published:
Last Updated:
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares make a handy gain on Monday after the firm received an upgrade from Morgan Stanley. The driving force behind this upgrade is Sarepta’s...
Published:
Last Updated:
Rigel Pharmaceuticals has suffered over the past year, but it seems this update may be the catalyst it has been looking for.
Published:
Last Updated:
24/7 Wall St. has collected several catalysts that are coming up in October for biotech and pharmaceutical companies.
Published:
Zogenix saw its shares more than double early on Friday after the company reported positive top-line results from its most recent late-stage trial in the treatment of Dravet syndrome.
Published:
Last Updated:
AbbVie shares made a handy gain on Thursday after it was announced that the company resolved its Humira patent disputes with Amgen.
Published:
Last Updated:
Zynerba Pharmaceuticals shares saw a huge gain early on Thursday after the firm announced positive results from its mid-stage cannabinoid trial.
Published:
Last Updated:
The September 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer's disease.
Published:
Last Updated:
Versartis shares absolutely cratered on Friday after the firm announced results from its late-stage Velocity clinical trial of somavaratan in pediatric growth hormone deficiency.
Published:
Last Updated:
As we have said before, updates from the FDA have the potential to make or break a company. In this case it seems like a mild setback, but further complications could prove to be catastrophic.
Published:
Last Updated: